Abstract 1668P
Background
There is scant attention given to the distress experienced by cancer patients or their caregivers in low-middle income countries like India. This study measures patient and caregiver distress in oncology and attempts to evaluate any correlation between the two.
Methods
All cancer patients ≥18 years and their primary caregiver were invited to participate in a survey which included demographic, disease, and therapy details, the NCCN distress scale for the patient and the Zarit Burden Interview (Short 12 items) questionnaire for the caregiver. An open-ended interview was used to record any additional problems.
Results
250 patients and corresponding caregivers completed the survey. 70.4% patients and 32.4% caregivers had moderate to severe distress burden. The average distress score for the patients and caregiver was 4.82 and 17.88 on the respective scales. Higher mean distress scores were seen in patients younger than 40 years, those from a rural background, having secondary or higher education and those on active or palliative treatment. Distress in patients was independent of gender, income group and hospital admission. Commonest care givers were sons (38.8%) and husbands (25.6%). Daughters as caregivers had the highest mean average burden (22.6). When scored individually, the question on enough time for oneself (Q1) and stress towards other responsibilities (Q2) had the highest mean scores (1.9) while the lowest average score (0.9) was found for the question regarding strain felt around patient. Open ended interview identified financial stress and sexual frustration as common causes cause of caregiver distress. On generating a scatter plot using linear regression, a definite trend was seen of rising patient distress with an increase in caregiver distress and Pearson’s Chi square test revealed a statistically significant association with the patient and caregiver distress scores (p <.0001).
Conclusions
There is significant unaddressed distress in both cancer patients and caregivers with a definite association between them. Open ended interviews also gave insight into causes of distress. Distress screening, co- counselling and early psycho-oncological interventions may help address these lacunae.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
N. Bisht.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1656TiP - The STAMPEDE2 niraparib-abiraterone acetate + prednisolone trial: A phase III, randomised, open-label trial in patients with metastatic prostate cancer (mPC) with a deleterious alteration in a homologous recombination repair (HRR) gene starting androgen deprivation therapy (ADT)
Presenter: Sarah Howlett
Session: Poster session 11
1658TiP - The STAMPEDE2 177Lutetium-PSMA-617 (177Lu-PSMA-617) trial: A phase III, randomised, open-label trial in patients with metastatic prostate cancer (mPC) starting androgen deprivation therapy (ADT)
Presenter: Minal Padden-Modi
Session: Poster session 11
1659TiP - A phase I, first-in-human, open-label, multicenter, trial-in-progress of the safety, tolerability, and preliminary efficacy of JNJ-87189401 (PSMA-CD28 bispecific antibody) combined with JNJ-78278343 (KLK2-CD3 bispecific antibody) for advanced prostate cancer
Presenter: Mark Stein
Session: Poster session 11
1660TiP - First-in-human study of ABBV-969, a dual variable antibody-drug conjugate (ADC), in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)
Presenter: Raanan Berger
Session: Poster session 11
1661TiP - SEGNO: An exploratory study of the safety and efficacy of genomic biomarker-guided neoadjuvant therapy for locally advanced and oligometastatic prostate cancer
Presenter: Haichao Huang
Session: Poster session 11
1662TiP - HARMONY: A phase II study of niraparib (N)/abiraterone acetate (AA) plus prednisone (P) for Hispanic/Latino (HL) and non-Hispanic Black (NHB) patients (pts) with metastatic hormone sensitive prostate cancer (mHSPC) and deleterious homologous recombination repair alterations (HRRa)
Presenter: Qian Qin
Session: Poster session 11
1664P - Early integration of psycho-oncology in cancer care: A model of care from a quaternary care government hospital in India and its patient related outcomes
Presenter: Niharika Bisht
Session: Poster session 11
1665P - Awareness of illness, psychological difficulties, and resources across life ages in early stage and metastatic cancer patients
Presenter: Raffaela Sartori
Session: Poster session 11